Thrombotic Thrombocytopenic Purpura: Symptoms, Causes, Treatment

What are the symptoms of thrombotic thrombocytopenic purpura?

Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that causes blood clots to form in small blood vessels throughout the body. This can lead to a variety of symptoms, including:

  1. Purpura: Small, purple or red spots on the skin (petechiae) caused by bleeding under the skin.
  2. Bruising: Easy or excessive bruising.
  3. Jaundice: Yellowing of the skin and eyes due to an accumulation of bilirubin in the blood, which can occur when red blood cells are destroyed.
  4. Pale or jaundiced skin: Due to anemia or jaundice.
  5. Fatigue: Weakness and fatigue due to anemia.
  6. Fever: Some people with TTP may develop a fever.
  7. Neurological symptoms: In severe cases, TTP can cause neurological symptoms such as confusion, weakness, numbness, or difficulty speaking or understanding speech.
  8. Shortness of breath: Difficulty breathing may occur if blood clots affect the lungs.
  9. Abdominal pain: Some people with TTP may experience abdominal pain, nausea, vomiting, or diarrhea.
  10. Kidney problems: TTP can cause kidney damage, leading to symptoms such as decreased urine output, swelling of the legs and ankles, and high blood pressure.
  11. Heart problems: In severe cases, TTP can affect the heart, leading to symptoms such as chest pain or palpitations.

It’s important to note that the symptoms of TTP can vary widely among individuals, and not everyone with TTP will experience all of these symptoms. TTP is a medical emergency and requires prompt treatment. If you or someone you know is experiencing symptoms of TTP, seek medical attention immediately.

What are the causes of thrombotic thrombocytopenic purpura?

Thrombotic thrombocytopenic purpura (TTP) is caused by a deficiency of an enzyme called ADAMTS13, which is responsible for cleaving a large protein called von Willebrand factor (vWF). When ADAMTS13 is deficient or not functioning properly, vWF is not cleaved as it should be, leading to the formation of large multimers of vWF. These large vWF multimers are more prone to binding platelets, which can lead to the formation of blood clots in small blood vessels throughout the body, causing the symptoms of TTP.

There are two main types of TTP based on the underlying cause:

  1. Acquired TTP: This is the most common form of TTP and is usually caused by the development of autoantibodies (immune proteins that attack the body’s own tissues) against ADAMTS13. These antibodies can inhibit the function of ADAMTS13, leading to a deficiency of the enzyme and the symptoms of TTP. Acquired TTP is often associated with other autoimmune disorders, such as systemic lupus erythematosus (SLE) or HIV infection.
  2. Hereditary TTP: This form of TTP is very rare and is caused by inherited mutations in the ADAMTS13 gene, leading to a deficiency of functional ADAMTS13 enzyme. Hereditary TTP is typically more severe and may present earlier in life than acquired TTP.

In addition to these primary causes, certain factors or conditions can trigger TTP in susceptible individuals. These triggers may include:

It’s important to note that while these triggers can increase the risk of developing TTP in susceptible individuals, not everyone who is exposed to these triggers will develop the condition. More research is needed to fully understand the complex interplay of factors that contribute to the development of TTP.

What is the treatment for thrombotic thrombocytopenic purpura?

The treatment for thrombotic thrombocytopenic purpura (TTP) typically involves a combination of therapies aimed at reducing platelet aggregation, replenishing ADAMTS13 levels, and treating the underlying cause if known. Treatment may include:

  1. Plasma exchange (plasmapheresis): This is the mainstay of treatment for TTP. Plasma exchange involves removing the patient’s plasma (which contains the antibodies against ADAMTS13) and replacing it with donor plasma or a plasma substitute. This helps to remove the antibodies and replenish ADAMTS13 levels, reducing the risk of further clot formation.
  2. Corticosteroids: Steroids such as prednisone may be used to suppress the immune system and reduce the production of antibodies against ADAMTS13.
  3. Rituximab: This is a monoclonal antibody that targets B cells, which are responsible for producing the antibodies against ADAMTS13. Rituximab may be used in combination with plasma exchange to reduce antibody production.
  4. Immunosuppressive therapy: Other immunosuppressive drugs, such as cyclophosphamide or vincristine, may be used in severe cases to further suppress the immune system.
  5. Treatment of underlying conditions: If TTP is triggered by an underlying condition, such as an infection or certain medications, treating the underlying cause may help to resolve the TTP.
  6. Supportive care: Supportive measures may be taken to manage complications of TTP, such as blood transfusions to treat severe anemia or medications to manage organ damage.
  7. Long-term management: Some people with TTP may require long-term treatment to prevent recurrence. This may include periodic plasma exchange or immunosuppressive therapy.

Early diagnosis and prompt initiation of treatment are essential in managing TTP and reducing the risk of complications. TTP is a serious condition that requires close monitoring and management by a hematologist or other healthcare provider experienced in treating blood disorders.

Share This Story, Choose Your Platform!

About the Author: John Scott

Leave A Comment